Multiple Myeloma — Trials

Multiple Myeloma — Trials · CancerIndex

Clinical trials

Registered studies

3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 814
Recruiting: 414
Ph III recruiting: 54
Growth YoY: +13.3%
Industry share: 29%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.1%
Trials / 1,000 deaths: 70.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (537)

clinicaltrialsPublishedShowing 51–82 of 82 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03227432	An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma	withdrawn	Phase 2	0	Dana-Farber Cancer InstituteOTHER	1	Aug 14, 2018	clinicaltrials
NCT02985333	Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma	withdrawn	Phase 2	0	Sun Yat-sen UniversityOTHER	1	May 14, 2018	clinicaltrials